Alkermes plc ALKS

NAS: ALKS | ISIN: IE00B56GVS15   24/04/2024
24,65 USD (+1,61%)
(+1,61%)   24/04/2024

24 april 2024 · Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 · Persbericht

17 april 2024 · Alkermes to Report First Quarter Financial Results on May 1, 2024 · Persbericht

9 april 2024 · Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia · Persbericht

8 april 2024 · Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society · Persbericht

7 maart 2024 · Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors · Persbericht

15 februari 2024 · Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 · Persbericht

8 februari 2024 · Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 · Persbericht

3 januari 2024 · Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

3 januari 2024 · Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan) · Persbericht

14 december 2023 · Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk · Persbericht

2 december 2023 · Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 · Persbericht

7 november 2023 · Alkermes to Participate in the Jefferies London Healthcare Conference · Persbericht

31 oktober 2023 · Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement · Persbericht

25 oktober 2023 · Alkermes plc Reports Third Quarter 2023 Financial Results · Persbericht

23 oktober 2023 · Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress · Persbericht

18 oktober 2023 · Alkermes to Report Third Quarter Financial Results on October 25, 2023 · Persbericht

10 oktober 2023 · Mural Oncology to Host Investor Webcast on October 17 · Persbericht

10 oktober 2023 · Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress · Persbericht

11 september 2023 · Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress · Persbericht

7 september 2023 · Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® Program · Persbericht

Mijn selecties